Table 1 Clinical characteristics of patients. Age (W = 370, p = 0.542) and sex (χ² = 0.937, p = 0.333) did not differ between MOG-IgG-seropositive patients and HCs

Subjects [N]

28

24

Number of eyes [N]

56

38

F/U [median years (min, max)]

1.9 (0.8–3.3)

1.9 (0.6–2.8)

Age [mean (SD)]; [range at baseline]

43.12 (9.76); [11–68]

40.66 (13.53); [15–68]

Sex [male (%)]

6 (21.4)

9 (37.5)

Clinical phenotypes (MOG-IgG-associated diseases)

–

ON (N = 7), NMOSD (N = 12), MS (N = 3), meningoencephalomyelitis (N = 2)

EDSS at baseline [median (IQR)]

–

2.5 (2.0; 3.0)

Disease duration at baseline in years [median (IQR)]

–

3.0(1.1; 8.8)

Eyes with a history of ON [Eye^ON+, N (%)]

–

20 (52.6%)

Patients with a history of ON [N (%)]

–

15 (62.5%)

Number of ON in Eye^ON+ [median (range)]

–

2 (1–8)

Eyes without a history of ON [Eye^ON-, N (%)]

–

18 (47.4%)

Time since ON [years; median (range)]

–

2.2 (0.4–14.9)

Eyes with contralateral ON during F/U [N (%)]

–

5 (13.2)

Treatment at baseline [N]

–

AZA [4], MTX [1], NAT [1], RIX [8], IVIG [1], PRED [2], NONE [7]